Subject: AEPP is Now ONCX CEO Issues Update on Progress to Investors

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
AEPP is Now ONCX CEO Issues Update on Progress to Investors
Hot Stock to WatchHot Stock to Watch

Company: Oncolix, Inc. (Pink Sheets: ONCX)

End of Day:

Price: 0.08

Change (%): + 0.02 (36.36)

Volume: 571,430
ONCX Chart

Oncolix, Inc., Continues Progress as an Emerging Clinical-Stage Biopharmaceutical Company with Stock Ticker Symbol Change to ONCX

New symbol becomes effective at opening of trading on November 29, 2017

HOUSTON, TEXAS - (Marketwired - Nov. 28, 2017) - Oncolix, Inc., (OTC PINK: AEPP) announced today that the Financial Industry Regulatory Authority (FINRA) has approved a change in the Company’s stock symbol to ONCX, effective at the opening of trading on November 29, 2017. The ticker symbol change is continued demonstration of progress toward positioning Oncolix as an emerging biopharmaceutical company with a clinical-stage asset.

“We are very much committed to building an innovative biopharmaceutical company and to furthering the development of Prolanta™, which is currently in an ongoing Phase I human clinical trial in ovarian cancer patients,” said Michael T. Redman, chief executive officer of Oncolix. “The ticker and name change and the recent appointment of an independent director on our board are continued evidence of our progress as a clinical-stage biopharmaceutical company. These are also important steps as we continue to build out the public company infrastructure to fulfill the OTC-QB listing requirements and ultimately a NASDAQ listing.”

Continue Reading

A Personal Letter to the Shareholders from Michael T. Redman, CEO of Oncolix, Inc.

HOUSTON, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Oncolix, Inc., (OTC PINK:ONCX) a company focused on developing new cancer therapeutics, announces a letter from the CEO.

My fellow shareholders,

First, I would like to thank you for investing in Oncolix. It is my responsibility to do everything in my power to enhance shareholder value. Since the merger on August 3 of this year, Oncolix has filed significant SEC documentation, completed a name change from Advanced Environmental Petroleum Producers to Oncolix and most recently, effectuated a stock ticker change from (OTC:AEPP) to (OTC:ONCX). This stock ticker change marks the end of an extensive review by the Financial Industry Regulatory Authority (FINRA) into our company’s business model, operations, and management team. We see this as a strong validation of who we are as a company and the progress that we have made to date. While we have been meeting all of our milestones and logistics issues, I do not believe that the company’s valuation reflects the value of the company and its lead asset, Prolanta. It is my belief that the short-term milestones that I will outline below should address this issue.

Following the ticker change, one of our top priorities is to uplist from Pink Sheets to an OTC-QB listing. To achieve this goal, we will be adding our second independent board member in the near future so that we meet all of the OTC-QB requirements. We believe you will be very impressed with our second independent board member. We also intend to commence our Scientific/Clinical Advisory board, which will consist of world-wide leaders that can provide guidance as we progress our drug Prolanta through the clinical trial process for the treatment of gynecological and breast cancers. Furthermore, we are actively pursuing both a Japanese and Chinese partner for investment, collaboration and to license rights to Prolanta for the Asian markets.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks